Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Squamous NSCLC 1Colonic Neoplasms 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × HLX07 × 1 year × Clear all
NCT07358585 2026-01-22

A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer

Shanghai Henlius Biotech

Phase 1/2 Not yet recruiting
126 enrolled
Gastrointestinal

Colonic Neoplasms

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Shanghai Henlius Biotech

Phase 2/3 Not yet recruiting
720 enrolled
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡